Novel FLT3 tyrosine kinase inhibitors

Bibliography

• BLUME-JENSEN P, HUNTER T: Oncogenic kinase signalling. Nature (2001) 411:355–365.
   PubMed Web of Science ®Google Scholar
• •An excellent review of receptor kinases and their role in cancer.
   Google Scholar
• ALEXANDER WS, NICOLA NA: Hemopoietic growth factor receptor abnormalities in leukemia. Leak. Res. (1998) 22:1097–1111.
   PubMed Web of Science ®Google Scholar
• REILLY IT: Class III receptor tyrosine kinases: role in leukaemogenesis. Br. J. Haematol. (2002) 116:744–757.
   PubMed Web of Science ®Google Scholar
• COOLS J, DEANGELO DJ, GOTLIB J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl. J. Med. (2003) 348:1201–1214.
   PubMed Web of Science ®Google Scholar
• GILLILAND DG, GRIFFIN JD: The roles of FLT3 in hematopoiesis and leukemia. Blood (2002) 100:1532–1542.
   PubMed Web of Science ®Google Scholar
• LEVIS M, SMALL D: FLT3: ITDoes matter in leukemia. Leukemia (2003) 17: 1738-1752.
   Google Scholar
• ••An up-to-date comprehensive review of therole of FLT3 in leukaemia.
   Google Scholar
• BISHOP JF: The treatment of adult acutemyeloid leukemia. Semin. Oncol. (1997) 24:57–69.
   PubMed Web of Science ®Google Scholar
• TSE KF, NOVELLI E, CIVIN CI, BOHMER FD, SMALL D: Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia (2001) 15:1001–1010.
   PubMed Web of Science ®Google Scholar
• LEVIS M, TSE KF, SMITH BD, GARRETT E, SMALL D: A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood(2001) 98:885–887.
   PubMed Web of Science ®Google Scholar
• •The findings described in this report are an important validation of FLT3 as a therapeutic target in AML. The study shows that leukaemic cells expressing FLT3/ITD mutations are selectively sensitive to FLT3 inhibition.
   Google Scholar
• LEVIS M, ALLEBACH J, TSE KF et al.: A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells M vitro and M vivo. Blood (2002) 99:3885–3891.
   PubMed Web of Science ®Google Scholar
• KELLY LM, YU JC, BOULTON CL et al.: CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell (2002) 1:421–432.
   PubMed Web of Science ®Google Scholar
• WEISBERG E, BOULTON C, KELLY LM et al.: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 1:433–443.
   PubMed Web of Science ®Google Scholar
• TELLERS, KRAMER D, BOHMER SA et al.: Bis(1H-2-indoly1)-1-methanones as inhibitors of the hematopoietic tyrosine kinase F1t3. Leukemia (2002) 16:1528–1534.
   PubMed Web of Science ®Google Scholar
• O'FARRELL AM, ABRAMS TJ, YUEN HA et al.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity M vitro and in vivo. Blood (2003) 101:3597–3605.
   Google Scholar
• YEE KW, O'FARRELL AM, SMOLICH BD et al.: 5U5416 and 5U5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood (2002) 100:2941–2949.
   Google Scholar
• GAZIT A, YEE K, UECKER A et al.: Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, F1t3 and Kit. Bioorg. Med. Chem. (2003) 11:2007–2018.
   PubMed Web of Science ®Google Scholar
• MURATA K, KUMAGAI H, KAWASHIMA T et al.: Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active FMS-like tyrosine kinase 3 (FLT3). J. Biol. Chem. (2003) 278(35)32892–32898
   Google Scholar
• ROSNET 0, SCHIFF C, PEBUSQUE MJ et al.: Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood (1993) 82:1110–1119.
   Google Scholar
• SMALL D, LEVENSTEIN M, KIM E et al.: STK-1, the human homolog of Flk-2/ Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Nati Acad. Sri. USA (1994) 91:459–463.
   PubMed Web of Science ®Google Scholar
• •Describes the cloning and expression of the human FLT3 gene.
   Google Scholar
• VAN DER GEER P, HUNTER T, LINDBERG RA: Receptor protein-tyrosine kinases and their signal transduction pathways. Ann. Rev Cell Biol. (1994) 10:251–337.
   PubMedGoogle Scholar
• WYBENGA-GROOT LE, BASKIN B, ONG SH et al.: Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell (2001) 106:745–757.
   PubMed Web of Science ®Google Scholar
• HUSE M, MUIR TW, XU L et al.: The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. MM. Cell (2001) 8:671–682.
   PubMed Web of Science ®Google Scholar
• HUBBARD SR: Theme and variations: juxtamembrane regulation of receptor protein kinases. MM. Cell (2001) 8:481–482.
   PubMed Web of Science ®Google Scholar
• DOSIL M, WANG S, LEMISCHKA IR: Mitogenic signalling and substrate specificity of the F1k2/F1t3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. MM. Cell. Biol. (1993) 13:6572–6585.
   Web of Science ®Google Scholar
• ROSNET 0, BUHRING HJ, DELAPEYRIERE 0 et al.: Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol. (1996) 95:218–223.
   Google Scholar
• LAVAGNA-SEVENIER C, MARCHETTO S, BIRNBAUM D, ROSNET 0: FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia (1998) 12:301–310.
   PubMed Web of Science ®Google Scholar
• LAVAGNA-SEVENIER C, MARCHETTO S, BIRNBAUM D, ROSNET 0: The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. Biol. Chem. (1998) 273:14962–14967.
   Web of Science ®Google Scholar
• ZHANG S, MANTEL C, BROXMEYER HE: F1t3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/F1t3 cells. J. Leukoc. Biol. (1999) 65:372–380.
   PubMed Web of Science ®Google Scholar
• MARCHETTO S, FOURNIER E, BESLU N et al.: SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia (1999) 13:1374–1382.
   PubMed Web of Science ®Google Scholar
• ZHANG S, FUKUDA S, LEE Y et al: Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for F1t3-dependent signaling. J. Exp. Med. (2000) 192:719–728.
   PubMed Web of Science ®Google Scholar
• HANNUM C, CULPEPPER J, CAMPBELL D et al.: Ligand for FLT3/ FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature (1994) 368:643–648.
   PubMed Web of Science ®Google Scholar
• LYMAN SD, JAMES L, JOHNSON L et al.: Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood (1994) 83:2795–2801.
   PubMed Web of Science ®Google Scholar
• GOTZE KS, RAMIREZ M, TABOR K et al.: Flt3high and Fit3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood (1998) 91: 1947-1958.
   Google Scholar
• MACKAREHTSCHIAN K, HARDIN JD, MOORE KA et al.: Targeted disruption of the flk2/f1t3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunig, (1995) 3:147–161.
   PubMed Web of Science ®Google Scholar
• MCKENNA HJ, STOCKING KL, MILLER RE et al.: Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood (2000) 95:3489–3497.
   PubMed Web of Science ®Google Scholar
• RAY RJ, PAIGE CJ, FURLONGER C, LYMAN SD, ROTTAPEL R: F1t3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Ear: Immunol (1996) 26:1504–1510.
   PubMed Web of Science ®Google Scholar
• VEIBY OP, JACOBSEN FW, CUI L, LYMAN SD, JACOBSEN SE: The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. Immunol (1996) 157:2953–2960.
   Google Scholar
• BROXMEYER HE, LU L, COOPERS et al.: F1t3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp. Hematol (1995) 23:1121–1129.
   PubMed Web of Science ®Google Scholar
• HIRAYAMA F, LYMAN SD, CLARK SC, OGAWA M: The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood(1995) 85: 1762-1768.
   Google Scholar
• NICHOLLS SE, WINTERS, MOTTRAM R, MIYAN JA, WHETTON AD: F1t3 ligand can promote survival and macrophage development without proliferation in myeloid progenitor cells. Exp. Hematol (1999) 27:663–672.
   PubMed Web of Science ®Google Scholar
• SITNICKA E, BUZA-VIDAS N, LARSSON S et al.: Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood (2003) 102:881–886.
   PubMed Web of Science ®Google Scholar
• MEIERHOFF G, DEHMEL U, GRUSS HJ et al.: Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia (1995) 9:1368–1372.
   PubMed Web of Science ®Google Scholar
• DREXLER HG: Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia (1996) 10:588–599.
   PubMed Web of Science ®Google Scholar
• CAROW CE, LEVENSTEIN M, KAUFMANN SH et al.: Expression of the hematopoietic growth factor receptor FLT3 (STK-1/F1k2) in human leukemias. Blood (1996) 87:1089–1096.
   PubMed Web of Science ®Google Scholar
• BIRG F, COURCOUL M, ROSNET 0 et al.: Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood (1992) 80:2584–2593.
   Google Scholar
• ROSNET 0, BUHRING HJ, MARCHETTO S et al.: Human FLT3/ FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia (1996) 10:238–248.
   Google Scholar
• NAKAO M, YOKOTA S, IWAI T et al.: Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia (1996) 10: 1911-1918.
   Google Scholar
• ••This is the original report of the discoveryof FLT3/ITD mutations in AML.
   Google Scholar
• KIYOI H, TOWATARI M, YOKOTA S et al.: Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia (1998) 12:1333–1337.
   PubMed Web of Science ®Google Scholar
• •This paper describes the demonstration that FLT3/ITD mutations constitutively activate the receptor.
   Google Scholar
• KIYOI H, NAOE T, NAKANO Y et al.: Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood (1999) 93:3074–3080.
   PubMed Web of Science ®Google Scholar
• ROMBOUTS WJ, BLOKLAND I, LOWENBERG B, PLOEMACHER RE: Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the F1t3 gene. Leukemia (2000) 14:675–683.
   PubMed Web of Science ®Google Scholar
• ABU-DUHIER FM, GOODEVE AC, WILSON GA et al.: FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br. Haematol (2000) 111:190–195.
   PubMed Web of Science ®Google Scholar
• STIRE WALT DL, KOPECKY KJ, MESHINCHI S et al: FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 97:3589–3595.
   PubMed Web of Science ®Google Scholar
• KOTTARIDIS PD, GALE RE, FREW ME et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood (2001) 98: 1752-1759.
   Google Scholar
• ••This was the first study to provide anindependent confirmation of the negative prognostic impact of FLT3/ITD mutations in a large cohort of AML patients.
   Google Scholar
• WHITMAN SP, ARCHER KJ, FENG L et al.: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. (2001) 61:7233–7239.
   PubMed Web of Science ®Google Scholar
• IWAI T, YOKOTA S, NAKAO M et al.: Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia (1999) 13:38–43.
   Google Scholar
• XU F, TAKI T, YANG HW et al.: Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br. Haematol (1999) 105:155–162.
   PubMed Web of Science ®Google Scholar
• KONDO M, HORIBE K, TAKAHASHI Y et al.: Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med. Pediatr. Oncol (1999) 33:525–529.
   PubMedGoogle Scholar
• MESHINCHI S, WOODS WG, STIREWALT DL et al: Prevalence and prognostic significance of F1t3 internal tandem duplication in pediatric acute myeloid leukemia. Blood (2001) 97:89–94.
   PubMed Web of Science ®Google Scholar
• THIEDE C, STEUDEL C, MOHR B et al.: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood (2002) 99:4326–4335.
   PubMed Web of Science ®Google Scholar
• SCHNITTGER S, SCHOCH C, DUGAS M et al.: Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood (2002) 100:59–66.
   PubMed Web of Science ®Google Scholar
• BOISSEL N, CAYUELA JM, PREUDHOMME C et al.: Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia (2002) 16: 1699-1704.
   Google Scholar
• TILL JH, ABLOOGLU AJ, FRANKEL M et al.: Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: insights into kinase mechanism. J. Biol. Chem. (2001) 276:10049–10055.
   PubMed Web of Science ®Google Scholar
• FURITSU T, TSUJIMURA T, TONO T et al.: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. Chu. Invest. (1993) 92:1736–1744.
   PubMed Web of Science ®Google Scholar
• JEFFERS M, SCHMIDT L, NAKAIGAWA N et al.: Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA (1997) 94:11445–11450.
   PubMed Web of Science ®Google Scholar
• SANTORO M, CARLOMAGNO F, ROMANO A et al.: Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (1995) 267:381–383.
   PubMed Web of Science ®Google Scholar
• BEGHINI A, PETERLONGO P, RIPAMONTI CB et al.: c-kit mutations in core binding factor leukemias. Blood (2000) 95:726–727.
   PubMed Web of Science ®Google Scholar
• NAGATA H, WOROBEC AS, OH CK et al.: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA (1995) 92:10560–10564.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO Y, KIYOI H, NAKANO Y et al.: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood (2001) 97:2434–2439.
   PubMed Web of Science ®Google Scholar
• ••The same group that identified the FLT3/ITD mutations herein describes the discovery of FLT3 kinase domain mutations in AML patients. This report also confirms that these mutations constitutively activate FLT3 but appear to have no prognostic impact.
   Google Scholar
• ABU-DUHIER FM, GOODEVE AC, WILSON GA et al.: Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. Haematol. (2001) 113:983–988.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl. Med. (2001) 344:1038–1042.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl. Med. (2001) 344:1031–1037.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl. I Med. (2002) 347:472–480.
   PubMed Web of Science ®Google Scholar
• LANGE B, VALTIERI M, SANTOLI D et al.: Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood (1987) 70:192–199.
   PubMed Web of Science ®Google Scholar
• MATSUO Y, MacLEOD RA, UPHOFF CC et al.: Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9) (q23;p22p23). Leukemia (1997) 11:1469–1477.
   PubMed Web of Science ®Google Scholar
• MOSMANN T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Immunol. Methods (1983) 65:55–63.
   PubMed Web of Science ®Google Scholar
• ORMEROD MG: The study of apoptotic cells by flow cytometry. Leukemia (1998) 12:1013–1025.
   PubMed Web of Science ®Google Scholar
• TSE KF, ALLEBACH J, LEVIS M et al.: Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia (2002) 16:2027–2036.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG SA, KUNG AL, MABON ME et al.: Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3:173–183.
   Google Scholar
• LAMERS MB, ANTSON AA, HUBBARD RE, SCOTT RK, WILLIAMS DH: Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine.Biol. (1999)285:713–725.
   Google Scholar
• BOHMER FD, KARAGYOZOV L, UECKER A et al.: A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J. Biol. Chem. (2003) 278:5148–5155.
   PubMed Web of Science ®Google Scholar
• NAGAR B, BORNMANN WG, PELLICENA P et al.: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD 173955 and imatinib (STI-571). Cancer Res. (2002) 62:4236–4243.
   PubMed Web of Science ®Google Scholar
• GRUNDLER R, THIEDE C, MIETHING C et al.: Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood (2003) 102:646–651.
   PubMed Web of Science ®Google Scholar
• KOVALENKO M, GAZIT A, BOHMER A et al.: Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. (1994) 54:6106–6114.
   PubMed Web of Science ®Google Scholar
• GAZIT A, APP H, MCMAHON G et al.:Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. I Med. Chem. (1996) 39:2170–2177.
   Google Scholar
• UEDA S, IKEDA H, MIZUKI M et al.: Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors 5T15 71 and AG1296. Int. I Hematol. (2002) 76:427–435.
   PubMed Web of Science ®Google Scholar
• GRIFFIN JH, LEUNG J, BRUNER RJ,CALIGIURI MA, BRIESEWITZ R: Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc. Natl. Acad. Sci. USA (2003) 100:7830–7835.
   PubMed Web of Science ®Google Scholar
• WHITMAN SP, GUIMOND M, BLASER B et al.: Primary acute myeloid leukemia (AML) cells with the FLT3 internal tandem duplication (ITD) and absence of wild type (WT) FLT3 (FLT3ITD/- genotype) are distinct from AML with either FLT3wt/wtor FLT3ITD/ wt genotypes. Blood (2002) 100:89a (Abstract).
   Google Scholar
• FONG TA, SHAWVER LK, SUN Let al.:5U5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59:99–106.
   Google Scholar
• MENDEL DB, LAIRD AD, SMOLICH BD et al.: Development of 5U5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anti-Cancer Drug Des. (2000) 15:29–41.
   PubMedGoogle Scholar
• SMOLICH BD, YUEN HA, WEST KA et al.: The antiangiogenic protein kinase inhibitors 5U5416 and 5U6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood (2001) 97:1413–1421.
   PubMed Web of Science ®Google Scholar
• GILES FJ, COOPER MA, SILVERMAN L et al: Phase II study of 5U5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases. Cancer (2003) 97: 1920-1928.
   Google Scholar
• MENDEL DB, LAIRD AD, XIN X et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. (2003) 9:327–337.
   PubMed Web of Science ®Google Scholar
• ABRAMS TJ, LEE LB, MURRAY LJ, PRYER NK, CHERRINGTON JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. (2003) 2:471–478.
   PubMed Web of Science ®Google Scholar
• RUEGG UT, BURGESS GM: Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci. (1989) 10:218–220.
   PubMed Web of Science ®Google Scholar
• YAMADA K, IWAHASHI K, KASE H: K252a, a new inhibitor of protein kinase C, concomitantly inhibits 40K protein phosphorylation and serotonin secretion in a phorbol ester-stimulated platelets. Biochem. Biophys. Res. Commun. (1987) 144:35–40.
   PubMed Web of Science ®Google Scholar
• NAKANISHI S, MATSUDA Y, IWAHASHI K, KASE H: K-252b, c and d, potent inhibitors of protein kinase C from microbial origin. Antibiot. (Tokyo) (1986) 39:1066–1071.
   PubMed Web of Science ®Google Scholar
• NAKANO H, KOBAYASHI E, TAKAHASHI I et al.: Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60. Antibiot. (Tokyo) (1987) 40:706–708.
   PubMed Web of Science ®Google Scholar
• GEORGE DJ, DIONNE CA, JANI Jet al.:Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. (1999) 59:2395–2401.
   Google Scholar
• FABBRO D, BUCHDUNGER E, WOOD J et al.: Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther. (1999) 82:293–301.
   PubMed Web of Science ®Google Scholar
• KELLY LM, LIU Q, KUTOK JL et al: FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood (2002) 99:310–318.
   PubMed Web of Science ®Google Scholar
• PANDEY A, VOLKOTS DL, SEROOGY JM et al.: Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. Med. Chem. (2002) 45:3772–3793.
   Web of Science ®Google Scholar
• YU JC, LOKKER NA, HOLLENBACH S et al.: Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. Pharmacol Exp. Ther. (2001) 298:1172–1178.
   PubMed Web of Science ®Google Scholar
• FIEDLER W, MESTERS R, TINNEFELD H et al.: A Phase II clinical study of 5U5416 in patients with refractory acute myeloid leukemia. Blood (2003)
   Google Scholar
• SMITH BD, LEVIS M, BROWN P et al.: Single agent CEP-701, a novel FLT-3 inhibitor, shows initial response in patients with refractory acute myeloid leukemia. Blood (2002) 100:85a (Abstract).
   Google Scholar
• STONE R, KLIMECK V, DEANGELO DJ et al: PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): a Phase II clinical trial. Blood (2002) 100:86a (Abstract).
   Google Scholar
• HEINRICH MC, DRUKER B, CURTIN P et al.: A 'first in man' study of the safety and PK/PD of an oral FLT3 inhibitor (MLN518) in patients with AML or high risk myelodysplasia. Blood (2002) 100:336a (Abstract).
   Google Scholar
• FORAN J, PAQUETTE R, COOPER MA et al.: A Phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed, or are not eligible for, conventional chemotherapy. Blood (2002) 100:558a (Abstract).
   Google Scholar